Literature DB >> 9714089

Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study.

M Pyörälä1, H Miettinen, M Laakso, K Pyörälä.   

Abstract

BACKGROUND: The Helsinki Policemen Study is one of the first prospective epidemiological studies demonstrating an association of hyperinsulinemia to the risk of coronary heart disease (CHD). The aim of the present study was to investigate the predictive value of hyperinsulinemia with regard to CHD risk during a 22-year follow-up of the Helsinki Policemen Study population. METHODS AND
RESULTS: The study was based on a cohort of 970 men who were 34 to 64 years of age and free of CHD, other cardiovascular disease, and diabetes. Risk factor measurements at baseline examination included an oral glucose tolerance test (OGTT) with blood glucose and plasma insulin measurements at 0, 1, and 2 hours. Area under the plasma insulin response curve (AUC insulin) during OGTT was used as a composite variable reflecting plasma insulin levels. During the 22-year follow-up, 164 men had a major CHD event (CHD death or nonfatal myocardial infarction). Age-adjusted hazard ratios for a major CHD event comparing men in the highest AUC insulin quintile with those in the combined 4 lower quintiles during 5-, 10-, 15-, and 22-year follow-up periods were 3.29 (95% CI, 1.56 to 6.91), 2.72 (95% CI, 1.67 to 4.42), 2.14 (95% CI, 1.43 to 3.21), and 1.61 (95% CI, 1.14 to 2.27), respectively. Further adjustment for other risk factors attenuated these hazard ratios to 2.36 (95% CI, 1.00 to 5.57), 2.29 (95% CI, 1.31 to 4.02), 1.76 (95% CI, 1.09 to 2.82), and 1.32 (95% CI, 0.89 to 1.97), respectively.
CONCLUSIONS: Hyperinsulinemia predicted CHD risk in Helsinki policemen over the 22-year follow-up, and to a large extent independently of other CHD risk factors, but its predictive value diminished with lengthening follow-up time.

Entities:  

Mesh:

Year:  1998        PMID: 9714089     DOI: 10.1161/01.cir.98.5.398

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  47 in total

Review 1.  Genetic determinants of diabetes and atherosclerosis.

Authors:  Braxton D Mitchell; Ikhide G Imumorin
Journal:  Curr Atheroscler Rep       Date:  2002-05       Impact factor: 5.113

2.  The CARDia trial protocol.

Authors:  D Smith
Journal:  Heart       Date:  2003-10       Impact factor: 5.994

3.  Gonadotrophin-releasing hormone agonists, diabetes and cardiovascular disease in men with prostate cancer: which metabolic syndrome?

Authors:  Matthew R Smith; A James O'Malley; Nancy L Keating
Journal:  BJU Int       Date:  2008-06       Impact factor: 5.588

Review 4.  New targets to treat obesity and the metabolic syndrome.

Authors:  Kathleen A Martin; Mitra V Mani; Arya Mani
Journal:  Eur J Pharmacol       Date:  2015-05-19       Impact factor: 4.432

Review 5.  The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  R Kahn; J Buse; E Ferrannini; M Stern
Journal:  Diabetologia       Date:  2005-09       Impact factor: 10.122

6.  Plasma insulin and cardiovascular mortality in non-diabetic European men and women: a meta-analysis of data from eleven prospective studies.

Authors: 
Journal:  Diabetologia       Date:  2004-07-07       Impact factor: 10.122

Review 7.  Mechanisms of endothelial dysfunction in the metabolic syndrome.

Authors:  Prakash C Deedwania
Journal:  Curr Diab Rep       Date:  2003-08       Impact factor: 4.810

Review 8.  Metabolic syndrome and cancer.

Authors:  Pooja Pothiwala; Sushil K Jain; Subhashini Yaturu
Journal:  Metab Syndr Relat Disord       Date:  2009-08       Impact factor: 1.894

Review 9.  Metabolic complications of androgen deprivation therapy for prostate cancer.

Authors:  Philip J Saylor; Matthew R Smith
Journal:  J Urol       Date:  2009-03-14       Impact factor: 7.450

Review 10.  Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy.

Authors:  Philip J Saylor; Nancy L Keating; Matthew R Smith
Journal:  J Gen Intern Med       Date:  2009-11       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.